Last reviewed · How we verify
GSK1838262 Placebo match
GSK1838262 is a placebo match formulation designed to mimic the appearance and administration of an active pharmaceutical agent for use in blinded clinical trials.
At a glance
| Generic name | GSK1838262 Placebo match |
|---|---|
| Sponsor | XenoPort, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
As a placebo match, GSK1838262 contains no active pharmaceutical ingredient and is formulated to be indistinguishable from the corresponding active drug in terms of appearance, taste, texture, and administration route. It is used in randomized controlled trials to maintain blinding and reduce bias in efficacy and safety assessments.
Approved indications
Common side effects
Key clinical trials
- Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study (PHASE4)
- Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK1838262 Placebo match CI brief — competitive landscape report
- GSK1838262 Placebo match updates RSS · CI watch RSS
- XenoPort, Inc. portfolio CI